Evidence map›Paper›PMID 37525937›Full record

ReviewBritish journal of pharmacology2024

Platelet P2Y

Emmanuel Boadi Amoafo, Philomena Entsie, Ying Kang, Ilaria Canobbio, Elisabetta Liverani

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Platelet-specific P2YRespiratory research · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Emmanuel Boadi AmoafoDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, North Dakota, USA.
Philomena EntsieDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, North Dakota, USA.
Ying KangDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, North Dakota, USA.
Ilaria CanobbioDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Elisabetta LiveraniDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, North Dakota, USA.ORCID 0009-0002-6321-3516
North Dakota State University · USUniversity of Pavia · IT

Funding

Sex-related variations in the response of drug therapies targeting purinergic signaling pathways in sepsisR21AI156627 · NIAID · NORTH DAKOTA STATE UNIVERSITY · PI LIVERANI, ELISABETTA · 2021 to 2022
$399k
NIAID NIH HHS R21 AI156627
6 · The paper itself

Abstract

Sepsis is a complicated pathological condition in response to severe infection. It is characterized by a strong systemic inflammatory response, where multiple components of the immune system are involved. Currently, there is no treatment for sepsis. Blood platelets are known for their role in haemostasis, but they also participate in inflammation through cell-cell interaction and the secretion of inflammatory mediators. Interestingly, an increase in platelet activation, secretion, and aggregation with other immune cells (such as monocytes, T-lymphocytes and neutrophils) has been detected in septic patients. Therefore, antiplatelet therapy in terms of P2Y

Indexed as

Blood PlateletsSepsisHumansImmunityPlatelet AggregationPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12age-related differencesG-protein coupled receptorsimmune responseP2Y12 signalling pathwaysplatelet activationplateletssex-related differences

Identifiers

PMID37525937
PMCPMC10830899
OpenAlexW4385442299

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.